Skip to content

CD4 T-Cell Count with Interferon-γ (IFN-γ) Stimulation (COVID-19 Specific)

Published: August 9, 2026Updated: August 16, 2026

This test measures your immune response by checking how your CD4 T-cells react to interferon-gamma when exposed to COVID-19 antigens. It helps assess your immune system’s ability to fight the virus.

Quick summary

["This test evaluates your immune response to COVID-19, focusing on how well your CD4 cells can activate when exposed to the virus."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
100859-8
Short code
CD4 IFNg/CD4 p Stim COVID Sp
Synonyms
CD4 IFNg/CD4 p Stim COVID Sp
Category
coagulation
Sample
whole-blood
Container
Lavender-top (EDTA)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Specimen volume
3 mL
Stability
Room temperature: 4h, Refrigerated: 24h
Hemolysis max
0
Lipemia max
0
Icterus max
0
TAT
4–24 hours
Order
routine

What Does This Test Measure?

The test involves collecting a blood sample to measure your CD4 T-cell count and their production of interferon-gamma (IFN-γ) after stimulation with COVID-19 antigens. This helps determine how effectively your immune system can respond to the virus.

Why Is This Test Done?

This test may be used to evaluate your immune response after COVID-19 infection, vaccination, or in cases where you have a weakened immune system. It can help doctors assess whether your immune cells are functioning properly to fight the virus.

How Is the Test Performed?

A blood sample is drawn from a vein, typically in your arm. The sample is then processed to measure CD4 T-cell activity and IFN-γ production after exposure to COVID-19 antigens. The results are compared to standard immune response benchmarks.

What Do the Results Mean?

Results show whether your CD4 T-cells are activating normally in response to COVID-19. Low or reduced responses may indicate an impaired immune reaction, while normal responses suggest a healthy immune response to the virus.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: This test is particularly useful for individuals with weakened immune systems (e.g., due to HIV, chemotherapy, or other conditions) to monitor their ability to fight COVID-19. It helps guide treatment decisions and assess recovery after infection or vaccination.

Short name

COVID-19 Stimulated IFN-γ CD4 T-Cell Response

Frequently asked questions

What does a low or normal response mean?
A low response may indicate your immune system is not activating CD4 T-cells effectively to fight COVID-19, which could affect your recovery or susceptibility to reinfection. A normal response suggests your immune system is functioning well in this context.
How long does it take to get results?
Results are typically available within 1 to 3 business days, depending on lab processing times. Your healthcare provider will discuss the findings with you during your follow-up visit.
Can this test be done at home?
No, this test requires a blood sample collected in a clinical setting by a healthcare professional. It is not a self-test and must be performed in a lab.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy